查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1570852

抗组织胺市场：按药物类型、给药途径、治疗疾病、最终用户、剂型划分 - 全球预测 2025-2030

Antihistamine Drugs Market by Drug Type, Route Of Administration, Diseases Treated, End User, Formulation - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年抗组织胺市场价值2.6534亿美元，预计到2024年将达到2.7974亿美元，复合年增长率为5.31%，到2030年将达到3.8139亿美元。

抗组织胺市场范围包括透过阻断组织胺受体来治疗过敏反应的药物。这些药物对于治疗过敏性鼻炎、结膜炎、荨麻疹和异位性皮肤炎等疾病至关重要。最终用户主要包括季节性过敏患者、医疗保健提供者以及依赖非处方药和处方笺的医疗机构。由于环境因素和遗传倾向导致全世界过敏症盛行率不断增加，对抗组织胺的需求持续增加。对过敏相关疾病的认识不断提高以及药物的获取便捷正在推动市场需求。影响市场的主要成长要素包括过敏原发生率的上升、非镇静药物製剂新兴市场的开拓以及更容易过敏的老年人口的不断增长。开发针对特定过敏反应的治疗方法以及对自然疗法不断增长的需求也具有潜力。公司应专注于第二代和第三代抗组织胺等创新，以最大限度地减少副作用并提高疗效，并探索与其他疗法的联合治疗。然而，市场面临一些限制，例如监管障碍和与某些抗组织胺相关的副作用，例如嗜睡，尤其是对于老年人。此外，学名药供应量的增加可能会导致价格竞争并影响利润率。此外，区分高度相似的抗组织胺药物仍然是一个挑战。需要创新，重点关注新的给药方法，例如儿科滴鼻剂和咀嚼片，并将其用途扩大到其他治疗领域，例如慢性搔痒症。市场竞争较少，重点是探索更安全、更有效的配方和替代疗法，推动可持续的业务成长，并开闢新的途径来解决快速增加的过敏率和多样化的应用。

主要市场统计
基准年[2023] 26534万美元
预测年份 [2024] 27974万美元
预测年份 [2030] 3.8139 亿美元
复合年增长率（%） 5.31%

市场动态：揭示快速发展的抗组织胺市场的关键市场洞察

供需的动态交互作用正在改变抗组织胺市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，以及消费行为及其对製造成本和采购成本的影响，也可以更清楚地了解其影响。

波特的五力：驾驭抗组织胺市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解抗组织胺市场的外部影响

外部宏观环境因素在塑造抗组织胺市场的表现动态中起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解抗组织胺市场的竞争状况

抗组织胺市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵抗组织胺市场供应商的绩效评估

FPNV 定位矩阵是评估抗组织胺市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘抗组织胺药物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，抗组织胺市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争格局中的挑战，利用新的商机并取得长期成功。

该报告提供了涵盖关键焦点细分市场的全面市场分析。

1. 市场渗透率：对当前市场环境的详细回顾。

2. 市场开拓：辨识新兴市场的成长机会，评估现有产业的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检视市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地过敏性疾病和过敏症状的盛行率不断增加，抗组织胺的需求不断增加。
      • 提高患者对过敏的认识和积极管理有助于市场成长
      • 增加非处方抗组织胺的可得性和可用性，提高消费者的承受能力
    • 抑制因素
      • 影响处方抗组织胺销售的价格敏感度和报销问题
    • 机会
      • 加强与医疗专业人员和过敏症专家的合作
      • 开发儿童友善抗组织胺药，扩大儿科过敏市场
    • 任务
      • 抗组织胺作为替代疗法越来越受欢迎和偏爱
  • 市场区隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章 抗组织胺市场：依药物类型

  • 介绍
  • 第一代H1抗组织胺药
    • 烷基胺
    • 乙醇胺
    • 乙二胺
    • 吩噻嗪
  • H2抗组织胺药
    • 西咪替丁
    • 法莫替丁
    • 尼扎替丁
    • 雷尼替丁
  • 鼻用抗组织胺药
    • 左卡巴斯汀
    • 奥洛他定
  • 第二代H1抗组织胺药
    • 阿克伐斯汀
    • 西替利嗪
  • 外用 H1 抗组织胺药
    • 氮卓斯汀
    • 奥洛他定

第七章 抗组织胺市场：依给药途径

  • 介绍
  • 鼻腔给药
    • 降低
    • 喷
  • 口服给药
    • 胶囊
    • 糖浆
    • 锭剂
  • 局部给药
    • 奶油
    • 凝胶

第八章抗组织胺市场：依治疗疾病分类

  • 介绍
  • 过敏性鼻炎
    • 常年性过敏性鼻炎
    • 季节性过敏性鼻炎
  • 慢性荨麻疹

第九章 抗组织胺市场：依最终用户分类

  • 介绍
  • 诊所
  • 居家医疗
  • 医院

第10章抗组织胺市场：按剂型

  • 介绍
  • 液体配方
    • 糖浆
  • 固态製剂
    • 胶囊
    • 锭剂

第十一章美洲抗组织胺市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太抗组织胺药物市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲抗组织胺市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议
Product Code: MRR-535C62918790

The Antihistamine Drugs Market was valued at USD 265.34 million in 2023, expected to reach USD 279.74 million in 2024, and is projected to grow at a CAGR of 5.31%, to USD 381.39 million by 2030.

The scope of the antihistamine drugs market encompasses pharmaceuticals used to treat allergic reactions by blocking histamine receptors. These drugs are essential in managing conditions like allergic rhinitis, conjunctivitis, urticaria, and atopic dermatitis. End-users largely include patients with seasonal allergies, healthcare providers, and institutions relying on over-the-counter and prescription formulations. The necessity of antihistamines continues to rise due to increasing prevalence of allergies worldwide, driven by environmental factors and genetic predispositions. The growing awareness of allergy-related ailments and accessibility to medication boost market demand. Key growth factors influencing the market include the rising incidence of allergens, developments in drug formulation offering non-sedative properties, and an expanding geriatric population who are more susceptible to allergies. The market also sees potential opportunities in developing targeted therapies for specific allergic responses and the growing demand for natural remedies. Companies should focus on innovations such as second- and third-generation antihistamines that minimize adverse effects and enhance efficacy, as well as exploring combinations with other therapeutic agents. However, the market faces limitations such as regulatory hurdles and the adverse effects associated with some antihistamines, like drowsiness, especially in older adults. Additionally, the increasing availability of generic drugs can lead to price competitions, impacting profit margins. Furthermore, a challenge persists in distinguishing antihistamine products amidst vast similarities. Innovations should focus on novel delivery methods, such as nasal sprays and chewable tablets for pediatric use, and expanding usage to other therapeutic areas like chronic pruritis. The market exhibits a moderately competitive nature with an emphasis on research for safer, more effective formulations and alternative therapies, fostering sustained business growth and opening new avenues for tackling burgeoning allergy rates and diversified applications.

KEY MARKET STATISTICS
Base Year [2023] USD 265.34 million
Estimated Year [2024] USD 279.74 million
Forecast Year [2030] USD 381.39 million
CAGR (%) 5.31%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antihistamine Drugs Market

The Antihistamine Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of allergic diseases and conditions worldwide boosting the demand for antihistamine drugs
    • Increasing awareness and proactive management of allergies among patients contributing to market growth
    • Growing over-the-counter availability and accessibility of antihistamine medications enhancing consumer purchase ease
  • Market Restraints
    • Price sensitivity and reimbursement issues affecting sales of prescription antihistamines
  • Market Opportunities
    • Increasing partnerships with healthcare providers and allergy specialists
    • Developing pediatric-friendly antihistamine drugs to capture the growing children's allergy market
  • Market Challenges
    • Rising popularity and preference for alternative therapies over antihistamine drugs

Porter's Five Forces: A Strategic Tool for Navigating the Antihistamine Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antihistamine Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antihistamine Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antihistamine Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antihistamine Drugs Market

A detailed market share analysis in the Antihistamine Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antihistamine Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antihistamine Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antihistamine Drugs Market

A strategic analysis of the Antihistamine Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antihistamine Drugs Market, highlighting leading vendors and their innovative profiles. These include Alcon Inc., Astellas Pharma Inc., AstraZeneca, Bayer AG, Boehringer Ingelheim, Dr. Reddy's Laboratories, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Johnson & Johnson, Mallinckrodt Pharmaceuticals, Meda AB, Merck Group, Mylan N.V., Novartis International AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd., and UCB S.A..

Market Segmentation & Coverage

This research report categorizes the Antihistamine Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across First-Generation H1-Antihistamines, H2-Antihistamines, Nasally Administered Antihistamines, Second-Generation H1-Antihistamines, and Topical H1-Antihistamines. The First-Generation H1-Antihistamines is further studied across Alkylamines, Ethanolamines, Ethylenediamines, and Phenothiazines. The H2-Antihistamines is further studied across Cimetidine, Famotidine, Nizatidine, and Ranitidine. The Nasally Administered Antihistamines is further studied across Levocabastine and Olopatadine. The Second-Generation H1-Antihistamines is further studied across Acrivastine and Cetirizine. The Topical H1-Antihistamines is further studied across Azelastine and Olopatadine.
  • Based on Route Of Administration, market is studied across Nasal Administration, Oral Administration, and Topical Administration. The Nasal Administration is further studied across Drops and Sprays. The Oral Administration is further studied across Capsules, Syrups, and Tablets. The Topical Administration is further studied across Creams and Gels.
  • Based on Diseases Treated, market is studied across Allergic Rhinitis and Chronic Urticaria. The Allergic Rhinitis is further studied across Perennial Allergic Rhinitis and Seasonal Allergic Rhinitis.
  • Based on End User, market is studied across Clinics, Home Care, and Hospitals.
  • Based on Formulation, market is studied across Liquid Formulations and Solid Formulations. The Liquid Formulations is further studied across Syrups. The Solid Formulations is further studied across Capsules and Tablets.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of allergic diseases and conditions worldwide boosting the demand for antihistamine drugs
      • 5.1.1.2. Increasing awareness and proactive management of allergies among patients contributing to market growth
      • 5.1.1.3. Growing over-the-counter availability and accessibility of antihistamine medications enhancing consumer purchase ease
    • 5.1.2. Restraints
      • 5.1.2.1. Price sensitivity and reimbursement issues affecting sales of prescription antihistamines
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing partnerships with healthcare providers and allergy specialists
      • 5.1.3.2. Developing pediatric-friendly antihistamine drugs to capture the growing children's allergy market
    • 5.1.4. Challenges
      • 5.1.4.1. Rising popularity and preference for alternative therapies over antihistamine drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antihistamine Drugs Market, by Drug Type

  • 6.1. Introduction
  • 6.2. First-Generation H1-Antihistamines
    • 6.2.1. Alkylamines
    • 6.2.2. Ethanolamines
    • 6.2.3. Ethylenediamines
    • 6.2.4. Phenothiazines
  • 6.3. H2-Antihistamines
    • 6.3.1. Cimetidine
    • 6.3.2. Famotidine
    • 6.3.3. Nizatidine
    • 6.3.4. Ranitidine
  • 6.4. Nasally Administered Antihistamines
    • 6.4.1. Levocabastine
    • 6.4.2. Olopatadine
  • 6.5. Second-Generation H1-Antihistamines
    • 6.5.1. Acrivastine
    • 6.5.2. Cetirizine
  • 6.6. Topical H1-Antihistamines
    • 6.6.1. Azelastine
    • 6.6.2. Olopatadine

7. Antihistamine Drugs Market, by Route Of Administration

  • 7.1. Introduction
  • 7.2. Nasal Administration
    • 7.2.1. Drops
    • 7.2.2. Sprays
  • 7.3. Oral Administration
    • 7.3.1. Capsules
    • 7.3.2. Syrups
    • 7.3.3. Tablets
  • 7.4. Topical Administration
    • 7.4.1. Creams
    • 7.4.2. Gels

8. Antihistamine Drugs Market, by Diseases Treated

  • 8.1. Introduction
  • 8.2. Allergic Rhinitis
    • 8.2.1. Perennial Allergic Rhinitis
    • 8.2.2. Seasonal Allergic Rhinitis
  • 8.3. Chronic Urticaria

9. Antihistamine Drugs Market, by End User

  • 9.1. Introduction
  • 9.2. Clinics
  • 9.3. Home Care
  • 9.4. Hospitals

10. Antihistamine Drugs Market, by Formulation

  • 10.1. Introduction
  • 10.2. Liquid Formulations
    • 10.2.1. Syrups
  • 10.3. Solid Formulations
    • 10.3.1. Capsules
    • 10.3.2. Tablets

11. Americas Antihistamine Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Antihistamine Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Antihistamine Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alcon Inc.
  • 2. Astellas Pharma Inc.
  • 3. AstraZeneca
  • 4. Bayer AG
  • 5. Boehringer Ingelheim
  • 6. Dr. Reddy's Laboratories
  • 7. Eli Lilly and Company
  • 8. F. Hoffmann-La Roche AG
  • 9. GlaxoSmithKline plc
  • 10. Johnson & Johnson
  • 11. Mallinckrodt Pharmaceuticals
  • 12. Meda AB
  • 13. Merck Group
  • 14. Mylan N.V.
  • 15. Novartis International AG
  • 16. Pfizer Inc.
  • 17. Sanofi
  • 18. Sun Pharmaceutical Industries Ltd
  • 19. Teva Pharmaceutical Industries Ltd.
  • 20. UCB S.A.

LIST OF FIGURES

  • FIGURE 1. ANTIHISTAMINE DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIHISTAMINE DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY DISEASES TREATED, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY DISEASES TREATED, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY FORMULATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS ANTIHISTAMINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS ANTIHISTAMINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES ANTIHISTAMINE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES ANTIHISTAMINE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANTIHISTAMINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC ANTIHISTAMINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTIHISTAMINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTIHISTAMINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ANTIHISTAMINE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. ANTIHISTAMINE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTIHISTAMINE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIHISTAMINE DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY FIRST-GENERATION H1-ANTIHISTAMINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY ALKYLAMINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY ETHANOLAMINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY ETHYLENEDIAMINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY PHENOTHIAZINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY FIRST-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY H2-ANTIHISTAMINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY CIMETIDINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY FAMOTIDINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY NIZATIDINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY RANITIDINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY H2-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY NASALLY ADMINISTERED ANTIHISTAMINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY LEVOCABASTINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY OLOPATADINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY NASALLY ADMINISTERED ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY SECOND-GENERATION H1-ANTIHISTAMINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY ACRIVASTINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY CETIRIZINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY SECOND-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL H1-ANTIHISTAMINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY AZELASTINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY OLOPATADINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY NASAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY DROPS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY SPRAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY NASAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY SYRUPS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY CREAMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY GELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY PERENNIAL ALLERGIC RHINITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY SEASONAL ALLERGIC RHINITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY CHRONIC URTICARIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY SYRUPS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 59. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 60. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY SOLID FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 61. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 62. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 63. GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS ANTIHISTAMINE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS ANTIHISTAMINE DRUGS MARKET SIZE, BY FIRST-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS ANTIHISTAMINE DRUGS MARKET SIZE, BY H2-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS ANTIHISTAMINE DRUGS MARKET SIZE, BY NASALLY ADMINISTERED ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 68. AMERICAS ANTIHISTAMINE DRUGS MARKET SIZE, BY SECOND-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 69. AMERICAS ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 70. AMERICAS ANTIHISTAMINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. AMERICAS ANTIHISTAMINE DRUGS MARKET SIZE, BY NASAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. AMERICAS ANTIHISTAMINE DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. AMERICAS ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. AMERICAS ANTIHISTAMINE DRUGS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
  • TABLE 75. AMERICAS ANTIHISTAMINE DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, 2018-2030 (USD MILLION)
  • TABLE 76. AMERICAS ANTIHISTAMINE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. AMERICAS ANTIHISTAMINE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 78. AMERICAS ANTIHISTAMINE DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 79. AMERICAS ANTIHISTAMINE DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 80. AMERICAS ANTIHISTAMINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 81. ARGENTINA ANTIHISTAMINE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. ARGENTINA ANTIHISTAMINE DRUGS MARKET SIZE, BY FIRST-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 83. ARGENTINA ANTIHISTAMINE DRUGS MARKET SIZE, BY H2-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 84. ARGENTINA ANTIHISTAMINE DRUGS MARKET SIZE, BY NASALLY ADMINISTERED ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 85. ARGENTINA ANTIHISTAMINE DRUGS MARKET SIZE, BY SECOND-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 86. ARGENTINA ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 87. ARGENTINA ANTIHISTAMINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. ARGENTINA ANTIHISTAMINE DRUGS MARKET SIZE, BY NASAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. ARGENTINA ANTIHISTAMINE DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. ARGENTINA ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. ARGENTINA ANTIHISTAMINE DRUGS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
  • TABLE 92. ARGENTINA ANTIHISTAMINE DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, 2018-2030 (USD MILLION)
  • TABLE 93. ARGENTINA ANTIHISTAMINE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. ARGENTINA ANTIHISTAMINE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 95. ARGENTINA ANTIHISTAMINE DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 96. ARGENTINA ANTIHISTAMINE DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 97. BRAZIL ANTIHISTAMINE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. BRAZIL ANTIHISTAMINE DRUGS MARKET SIZE, BY FIRST-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 99. BRAZIL ANTIHISTAMINE DRUGS MARKET SIZE, BY H2-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 100. BRAZIL ANTIHISTAMINE DRUGS MARKET SIZE, BY NASALLY ADMINISTERED ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 101. BRAZIL ANTIHISTAMINE DRUGS MARKET SIZE, BY SECOND-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 102. BRAZIL ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 103. BRAZIL ANTIHISTAMINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. BRAZIL ANTIHISTAMINE DRUGS MARKET SIZE, BY NASAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. BRAZIL ANTIHISTAMINE DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. BRAZIL ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. BRAZIL ANTIHISTAMINE DRUGS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
  • TABLE 108. BRAZIL ANTIHISTAMINE DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, 2018-2030 (USD MILLION)
  • TABLE 109. BRAZIL ANTIHISTAMINE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. BRAZIL ANTIHISTAMINE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 111. BRAZIL ANTIHISTAMINE DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 112. BRAZIL ANTIHISTAMINE DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 113. CANADA ANTIHISTAMINE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. CANADA ANTIHISTAMINE DRUGS MARKET SIZE, BY FIRST-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 115. CANADA ANTIHISTAMINE DRUGS MARKET SIZE, BY H2-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 116. CANADA ANTIHISTAMINE DRUGS MARKET SIZE, BY NASALLY ADMINISTERED ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 117. CANADA ANTIHISTAMINE DRUGS MARKET SIZE, BY SECOND-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 118. CANADA ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 119. CANADA ANTIHISTAMINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. CANADA ANTIHISTAMINE DRUGS MARKET SIZE, BY NASAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. CANADA ANTIHISTAMINE DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. CANADA ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. CANADA ANTIHISTAMINE DRUGS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
  • TABLE 124. CANADA ANTIHISTAMINE DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, 2018-2030 (USD MILLION)
  • TABLE 125. CANADA ANTIHISTAMINE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. CANADA ANTIHISTAMINE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 127. CANADA ANTIHISTAMINE DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 128. CANADA ANTIHISTAMINE DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 129. MEXICO ANTIHISTAMINE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. MEXICO ANTIHISTAMINE DRUGS MARKET SIZE, BY FIRST-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 131. MEXICO ANTIHISTAMINE DRUGS MARKET SIZE, BY H2-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 132. MEXICO ANTIHISTAMINE DRUGS MARKET SIZE, BY NASALLY ADMINISTERED ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 133. MEXICO ANTIHISTAMINE DRUGS MARKET SIZE, BY SECOND-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 134. MEXICO ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 135. MEXICO ANTIHISTAMINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. MEXICO ANTIHISTAMINE DRUGS MARKET SIZE, BY NASAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. MEXICO ANTIHISTAMINE DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. MEXICO ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. MEXICO ANTIHISTAMINE DRUGS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
  • TABLE 140. MEXICO ANTIHISTAMINE DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, 2018-2030 (USD MILLION)
  • TABLE 141. MEXICO ANTIHISTAMINE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 142. MEXICO ANTIHISTAMINE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 143. MEXICO ANTIHISTAMINE DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 144. MEXICO ANTIHISTAMINE DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED STATES ANTIHISTAMINE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED STATES ANTIHISTAMINE DRUGS MARKET SIZE, BY FIRST-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED STATES ANTIHISTAMINE DRUGS MARKET SIZE, BY H2-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED STATES ANTIHISTAMINE DRUGS MARKET SIZE, BY NASALLY ADMINISTERED ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED STATES ANTIHISTAMINE DRUGS MARKET SIZE, BY SECOND-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 150. UNITED STATES ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 151. UNITED STATES ANTIHISTAMINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. UNITED STATES ANTIHISTAMINE DRUGS MARKET SIZE, BY NASAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. UNITED STATES ANTIHISTAMINE DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. UNITED STATES ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. UNITED STATES ANTIHISTAMINE DRUGS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
  • TABLE 156. UNITED STATES ANTIHISTAMINE DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, 2018-2030 (USD MILLION)
  • TABLE 157. UNITED STATES ANTIHISTAMINE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. UNITED STATES ANTIHISTAMINE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 159. UNITED STATES ANTIHISTAMINE DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 160. UNITED STATES ANTIHISTAMINE DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 161. UNITED STATES ANTIHISTAMINE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC ANTIHISTAMINE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC ANTIHISTAMINE DRUGS MARKET SIZE, BY FIRST-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC ANTIHISTAMINE DRUGS MARKET SIZE, BY H2-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC ANTIHISTAMINE DRUGS MARKET SIZE, BY NASALLY ADMINISTERED ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC ANTIHISTAMINE DRUGS MARKET SIZE, BY SECOND-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC ANTIHISTAMINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC ANTIHISTAMINE DRUGS MARKET SIZE, BY NASAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC ANTIHISTAMINE DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC ANTIHISTAMINE DRUGS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC ANTIHISTAMINE DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, 2018-2030 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC ANTIHISTAMINE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC ANTIHISTAMINE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC ANTIHISTAMINE DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC ANTIHISTAMINE DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC ANTIHISTAMINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 179. AUSTRALIA ANTIHISTAMINE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. AUSTRALIA ANTIHISTAMINE DRUGS MARKET SIZE, BY FIRST-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 181. AUSTRALIA ANTIHISTAMINE DRUGS MARKET SIZE, BY H2-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 182. AUSTRALIA ANTIHISTAMINE DRUGS MARKET SIZE, BY NASALLY ADMINISTERED ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 183. AUSTRALIA ANTIHISTAMINE DRUGS MARKET SIZE, BY SECOND-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 184. AUSTRALIA ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 185. AUSTRALIA ANTIHISTAMINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. AUSTRALIA ANTIHISTAMINE DRUGS MARKET SIZE, BY NASAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. AUSTRALIA ANTIHISTAMINE DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. AUSTRALIA ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. AUSTRALIA ANTIHISTAMINE DRUGS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
  • TABLE 190. AUSTRALIA ANTIHISTAMINE DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, 2018-2030 (USD MILLION)
  • TABLE 191. AUSTRALIA ANTIHISTAMINE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 192. AUSTRALIA ANTIHISTAMINE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 193. AUSTRALIA ANTIHISTAMINE DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 194. AUSTRALIA ANTIHISTAMINE DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 195. CHINA ANTIHISTAMINE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. CHINA ANTIHISTAMINE DRUGS MARKET SIZE, BY FIRST-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 197. CHINA ANTIHISTAMINE DRUGS MARKET SIZE, BY H2-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 198. CHINA ANTIHISTAMINE DRUGS MARKET SIZE, BY NASALLY ADMINISTERED ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 199. CHINA ANTIHISTAMINE DRUGS MARKET SIZE, BY SECOND-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 200. CHINA ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 201. CHINA ANTIHISTAMINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 202. CHINA ANTIHISTAMINE DRUGS MARKET SIZE, BY NASAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 203. CHINA ANTIHISTAMINE DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 204. CHINA ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 205. CHINA ANTIHISTAMINE DRUGS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
  • TABLE 206. CHINA ANTIHISTAMINE DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, 2018-2030 (USD MILLION)
  • TABLE 207. CHINA ANTIHISTAMINE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 208. CHINA ANTIHISTAMINE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 209. CHINA ANTIHISTAMINE DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 210. CHINA ANTIHISTAMINE DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 211. INDIA ANTIHISTAMINE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. INDIA ANTIHISTAMINE DRUGS MARKET SIZE, BY FIRST-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 213. INDIA ANTIHISTAMINE DRUGS MARKET SIZE, BY H2-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 214. INDIA ANTIHISTAMINE DRUGS MARKET SIZE, BY NASALLY ADMINISTERED ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 215. INDIA ANTIHISTAMINE DRUGS MARKET SIZE, BY SECOND-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 216. INDIA ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 217. INDIA ANTIHISTAMINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 218. INDIA ANTIHISTAMINE DRUGS MARKET SIZE, BY NASAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 219. INDIA ANTIHISTAMINE DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 220. INDIA ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 221. INDIA ANTIHISTAMINE DRUGS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
  • TABLE 222. INDIA ANTIHISTAMINE DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, 2018-2030 (USD MILLION)
  • TABLE 223. INDIA ANTIHISTAMINE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 224. INDIA ANTIHISTAMINE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 225. INDIA ANTIHISTAMINE DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 226. INDIA ANTIHISTAMINE DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 227. INDONESIA ANTIHISTAMINE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. INDONESIA ANTIHISTAMINE DRUGS MARKET SIZE, BY FIRST-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 229. INDONESIA ANTIHISTAMINE DRUGS MARKET SIZE, BY H2-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 230. INDONESIA ANTIHISTAMINE DRUGS MARKET SIZE, BY NASALLY ADMINISTERED ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 231. INDONESIA ANTIHISTAMINE DRUGS MARKET SIZE, BY SECOND-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 232. INDONESIA ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 233. INDONESIA ANTIHISTAMINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 234. INDONESIA ANTIHISTAMINE DRUGS MARKET SIZE, BY NASAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 235. INDONESIA ANTIHISTAMINE DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 236. INDONESIA ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 237. INDONESIA ANTIHISTAMINE DRUGS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
  • TABLE 238. INDONESIA ANTIHISTAMINE DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, 2018-2030 (USD MILLION)
  • TABLE 239. INDONESIA ANTIHISTAMINE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 240. INDONESIA ANTIHISTAMINE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 241. INDONESIA ANTIHISTAMINE DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 242. INDONESIA ANTIHISTAMINE DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 243. JAPAN ANTIHISTAMINE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 244. JAPAN ANTIHISTAMINE DRUGS MARKET SIZE, BY FIRST-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 245. JAPAN ANTIHISTAMINE DRUGS MARKET SIZE, BY H2-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 246. JAPAN ANTIHISTAMINE DRUGS MARKET SIZE, BY NASALLY ADMINISTERED ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 247. JAPAN ANTIHISTAMINE DRUGS MARKET SIZE, BY SECOND-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 248. JAPAN ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 249. JAPAN ANTIHISTAMINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 250. JAPAN ANTIHISTAMINE DRUGS MARKET SIZE, BY NASAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 251. JAPAN ANTIHISTAMINE DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 252. JAPAN ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 253. JAPAN ANTIHISTAMINE DRUGS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
  • TABLE 254. JAPAN ANTIHISTAMINE DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, 2018-2030 (USD MILLION)
  • TABLE 255. JAPAN ANTIHISTAMINE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 256. JAPAN ANTIHISTAMINE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 257. JAPAN ANTIHISTAMINE DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 258. JAPAN ANTIHISTAMINE DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 259. MALAYSIA ANTIHISTAMINE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. MALAYSIA ANTIHISTAMINE DRUGS MARKET SIZE, BY FIRST-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 261. MALAYSIA ANTIHISTAMINE DRUGS MARKET SIZE, BY H2-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 262. MALAYSIA ANTIHISTAMINE DRUGS MARKET SIZE, BY NASALLY ADMINISTERED ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 263. MALAYSIA ANTIHISTAMINE DRUGS MARKET SIZE, BY SECOND-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 264. MALAYSIA ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 265. MALAYSIA ANTIHISTAMINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 266. MALAYSIA ANTIHISTAMINE DRUGS MARKET SIZE, BY NASAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 267. MALAYSIA ANTIHISTAMINE DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 268. MALAYSIA ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 269. MALAYSIA ANTIHISTAMINE DRUGS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
  • TABLE 270. MALAYSIA ANTIHISTAMINE DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, 2018-2030 (USD MILLION)
  • TABLE 271. MALAYSIA ANTIHISTAMINE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 272. MALAYSIA ANTIHISTAMINE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 273. MALAYSIA ANTIHISTAMINE DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 274. MALAYSIA ANTIHISTAMINE DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 275. PHILIPPINES ANTIHISTAMINE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. PHILIPPINES ANTIHISTAMINE DRUGS MARKET SIZE, BY FIRST-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 277. PHILIPPINES ANTIHISTAMINE DRUGS MARKET SIZE, BY H2-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 278. PHILIPPINES ANTIHISTAMINE DRUGS MARKET SIZE, BY NASALLY ADMINISTERED ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 279. PHILIPPINES ANTIHISTAMINE DRUGS MARKET SIZE, BY SECOND-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 280. PHILIPPINES ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 281. PHILIPPINES ANTIHISTAMINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 282. PHILIPPINES ANTIHISTAMINE DRUGS MARKET SIZE, BY NASAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 283. PHILIPPINES ANTIHISTAMINE DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 284. PHILIPPINES ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 285. PHILIPPINES ANTIHISTAMINE DRUGS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
  • TABLE 286. PHILIPPINES ANTIHISTAMINE DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, 2018-2030 (USD MILLION)
  • TABLE 287. PHILIPPINES ANTIHISTAMINE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 288. PHILIPPINES ANTIHISTAMINE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 289. PHILIPPINES ANTIHISTAMINE DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 290. PHILIPPINES ANTIHISTAMINE DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 291. SINGAPORE ANTIHISTAMINE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 292. SINGAPORE ANTIHISTAMINE DRUGS MARKET SIZE, BY FIRST-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 293. SINGAPORE ANTIHISTAMINE DRUGS MARKET SIZE, BY H2-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 294. SINGAPORE ANTIHISTAMINE DRUGS MARKET SIZE, BY NASALLY ADMINISTERED ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 295. SINGAPORE ANTIHISTAMINE DRUGS MARKET SIZE, BY SECOND-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 296. SINGAPORE ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 297. SINGAPORE ANTIHISTAMINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 298. SINGAPORE ANTIHISTAMINE DRUGS MARKET SIZE, BY NASAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 299. SINGAPORE ANTIHISTAMINE DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 300. SINGAPORE ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 301. SINGAPORE ANTIHISTAMINE DRUGS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
  • TABLE 302. SINGAPORE ANTIHISTAMINE DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, 2018-2030 (USD MILLION)
  • TABLE 303. SINGAPORE ANTIHISTAMINE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 304. SINGAPORE ANTIHISTAMINE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 305. SINGAPORE ANTIHISTAMINE DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 306. SINGAPORE ANTIHISTAMINE DRUGS MARKET SIZE, BY SOLID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 307. SOUTH KOREA ANTIHISTAMINE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 308. SOUTH KOREA ANTIHISTAMINE DRUGS MARKET SIZE, BY FIRST-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 309. SOUTH KOREA ANTIHISTAMINE DRUGS MARKET SIZE, BY H2-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 310. SOUTH KOREA ANTIHISTAMINE DRUGS MARKET SIZE, BY NASALLY ADMINISTERED ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 311. SOUTH KOREA ANTIHISTAMINE DRUGS MARKET SIZE, BY SECOND-GENERATION H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 312. SOUTH KOREA ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL H1-ANTIHISTAMINES, 2018-2030 (USD MILLION)
  • TABLE 313. SOUTH KOREA ANTIHISTAMINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 314. SOUTH KOREA ANTIHISTAMINE DRUGS MARKET SIZE, BY NASAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 315. SOUTH KOREA ANTIHISTAMINE DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 316. SOUTH KOREA ANTIHISTAMINE DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 317. SOUTH KOREA ANTIHISTAMINE DRUGS MARKET SIZE, BY DISEASES TREATED, 2018-2030 (USD MILLION)
  • TABLE 318. SOUTH KOREA ANTIHISTAMINE DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, 2018-2030 (USD MILLION)
  • TABLE 319. SOUTH KOREA ANTIHISTAMINE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 320. SOUTH KOREA ANTIHISTAMINE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 321. SOUTH KOREA ANTIHISTAMINE DRUGS MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 322. SOUTH KOREA ANTIHISTAMINE DRUGS MARKET SIZE, BY SOLID F